AGP Executive Report
Last update: 7 hours agoUS–Liechtenstein Pharma Trade: The US Commerce Department has put Liechtenstein (along with 19 other jurisdictions) on a zero-tariff list for specific speciality medicines and related ingredients, even as a broader 100% tariff on certain patented pharma imports ramps up from Sept. 29. The exemption is product-specific (rare diseases, fertility drugs, cell and gene therapies, antibody-drug conjugates, nuclear and plasma-derived therapies, plus some veterinary products) and hinges on qualifying under an eligible trade/security framework. Healthcare Workforce Policy: Ireland is temporarily relaxing a “50:50 rule” limiting non-EEA workers to half of an organisation’s staff to ease healthcare shortages—an issue that has hit nursing homes, home-care and disability services hardest. EU Biotech Access: Neuraxpharm’s NEZGLYAL® (leriglitazone) has received EU marketing authorisation under exceptional circumstances for childhood cerebral adrenoleukodystrophy, with Germany expected to be the first launch market. Cross-border Industry Links: The Việt Nam–EFTA free trade deal is expected to open new export opportunities for seafood, but firms will need to meet stricter quality, traceability and sustainability requirements.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.